SPCC (Sharing Progress in Cancer Care) shared the following on LinkedIn:
“HR+/HER2- MBC treatment landscape: what’s next? Join our upcoming expert-led webinar on 29 January 2025 at 18:00 CET.
Discussant: Miguel Martin (ES)
Experts: Patrick Neven (BE), Joyce O’Shaughnessy (US)
Key topics:
- Latest HR+ HER2- MBC data and future treatment landscape
- Biomarker testing
- Biomarker vs non-biomarker driven treatment choices
- Sequencing therapies: current and future approaches tailored to clinical characteristics
Register here (free of charge).
This webinar is supported by an unrestricted educational grant from Eli Lilly.”
